Endometriosis ~ Abdominal Pain ~ Endo ~ Scar Tissue ~ Adhesions ~ Infertility ~ Hysterectomy

Monday, January 08, 2007

Neurocrine Biosciences Announces Positive Results From Second Phase II Study With Its Orally Active GnRH Receptor Antagonist in Endometriosis

SAN DIEGO, Jan. 8 -- Neurocrine Biosciences, Inc. today announced positive preliminary results from its second 'proof of concept', safety and efficacy Phase II clinical trial over a 3-month treatment period using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist (NBI-56418) in patients with endometriosis. In 2006, the Company previously reported positive results from the completion of the first 3-month 'proof of concept' double-blind treatment period and additional 3-month follow up period of a parallel Phase II exploratory trial with NBI-56418 given once daily to endometriosis patients. This second exploratory study, which was also started in 2006, was designed to evaluate dose-response and twice daily dosing.
Read More

No comments: